0000899243-23-002674.txt : 20230125 0000899243-23-002674.hdr.sgml : 20230125 20230125180431 ACCESSION NUMBER: 0000899243-23-002674 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230123 FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meisner Lara CENTRAL INDEX KEY: 0001883986 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 23553417 MAIL ADDRESS: STREET 1: C/O VIRIDIAN THERAPEUTICS, INC. STREET 2: 203 CRESCENT STREET, BLDG. 17, SUITE 102 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-23 0 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001883986 Meisner Lara C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 0 1 0 0 General Counsel and Secretary Common Stock 2023-01-23 4 M 0 4971 23.03 A 4971 D Common Stock 2023-01-23 4 M 0 1872 14.00 A 6843 D Common Stock 2023-01-23 4 S 0 6843 35.66 D 0 D Stock Option (Right to Buy) 23.03 2023-01-23 4 M 0 4971 0.00 D 2031-01-18 Common Stock 4971 39750 D Stock Option (Right to Buy) 14.00 2023-01-23 4 M 0 1872 0.00 D 2031-09-22 Common Stock 1872 20003 D This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. /s/ Kristian Humer, Attorney-in-Fact for Lara Meisner 2023-01-25